Invitrocue - Transforming bioanalytics

Press Releases

International MOU inked between chemistry and biomedical talents from Hong Kong, Singapore and Europe for late-stage cancer research enhancement.

The two research institutes in this collaboration are both located in the Hong Kong Science Park, including the LSCCB funded by the Innovation and Technology Commission’s Health@InnoHK innovation platform, and the Hong Kong Science and Technology Park Corporation partner company Invitrocue (Hong Kong). Read More (English)Read More (Traditional Chinese)Read More (Simplified Chinese) This event has …

Read more

Launch of New Joint Innovation Laboratory to Advance Personalised Medicine for Cancer Treatment

L-R: Dr Benjamin Seet, Executive Director of the Biomedical Research Council, A*STAR; His Excellency Bruce Gosper, the Australian High Commissioner to Singapore; Dr Steven Fang, Chief Executive Officer / Founder, Invitrocue Ltd; The Hon Martin Hamilton Smith, Minister for Trade and Investment, South Australian Government; Dr Raj Thampuran, Managing Director, A*STAR; Professor Ng Huck Hui, …

Read more

Invitrocue to work with Garvan Institute to Progress Personalised Real-time Screening of Cancer Drugs

July 03, 2017 – Invitrocue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions providers, is pleased to announce that it has been granted Human Research Ethics Committee approval to understand a cancer research study with Sydney’s Garvan Institute of Medical Research, to provide further clinical validation of Invitrocue technology for use in personalised real-time screening of …

Read more

Invitrocue Expands Into In-Vitro Skin and Wound Healing Assays

22 May, 2017 – Invitrocue (ASX:IVQ) announced today that it will be expanding its cell-based assaying business into skin and wound healing. Invitrocue will develop robust and easy-to-use in vitro assays to assess the safety and effectiveness of consumer antiseptics and over-the-counter (OTC) wound dressing products. Invitrocue has signed a Master Services Agreement with Mundipharma …

Read more